Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Carcinoma, Adenoid Cystic Clinical Trial

Official title: Tyrosine Kinase Inhibitors in the Management of Local Advanced or Metastastic Adenoid Cystic Carcinoma

Status Recruiting

Clinical Trial Summary

There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma.

This is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.

Clinical Trial Description

The histologic appearance of adenoid cystic carcinoma is low grade, management of this malignancy is a challenge because of its insidious local growth pattern and lack of effency with chemotherapy or radiotherapy in metastatic disease.

In other performed clinical trials, objective responses to any cytotoxic agent or regimen are infrequent, whereas stabilization of disease was observed more commonly.

In adenoid cystic carcinoma, the study focusing on EGFR pathway is rare. According to previous study, adenoid cystic carcinoma cell lines have increased pAkt activity when EGF-stimulation is added. And when treated with EGFR/VEGFR TK dual inhibitor, the phosphorylated form of Akt decreased despite of total level of Akt is remained unchanged. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Adenoid Cystic

• NCT number: NCT04974866
• Study type: Interventional
• Source: Qingdao Central Hospital
• Status: Recruiting
• Phase: Phase 2
• Start date: July 1, 2021
• Completion date: July 31, 2026